Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05346172 · ClinicalTrials.gov registry record
The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction
A clinical trial, sponsored by Research Insight.
- Completed
- Registry status
- 60
- Enrollment target
NCT05346172: Completed study, sponsored by Research Insight.
NCT05346172 is a clinical trial that has completed, run by Research Insight. The registered enrollment target is 60 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05346172 has completed, sponsored by Research Insight.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
This will be a single arm, open-label, prospective study of patient-reported outcomes of patients with bilateral implantation of the Panoptix or Panoptix Toric implant.
Primary Outcome
Percentage of patients who notice glare or haloes around lights in dim light situations
Interventions
- DEVICE PanOptix or PanOptix Toric IOL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2022-06-17 |
| Est. Completion | 2023-03-10 |
What the finished NCT05346172 record still lists
NCT05346172 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 60 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which PanOptix or PanOptix Toric IOL is the first listed.
NCT05346172 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05346172 about?
NCT05346172 is a clinical study titled "The Clareon PanOptix Trifocal IOL: Visual Outcomes and Patient Satisfaction". This will be a single arm, open-label, prospective study of patient-reported outcomes of patients with bilateral implantation of the Panoptix or Panoptix Toric implant.
What is the current status of trial NCT05346172?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2022-06-17. Estimated completion is 2023-03-10.
What interventions are being tested in trial NCT05346172?
The interventions under investigation include: PanOptix or PanOptix Toric IOL (DEVICE).
Who is sponsoring clinical trial NCT05346172?
This trial is sponsored by Research Insight, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI